<DOC>
	<DOCNO>NCT02555059</DOCNO>
	<brief_summary>The objective study collect post-marketing information safety efficacy Ciproxan injection routine clinical practice .</brief_summary>
	<brief_title>Special Drug Use Investigation Ciproxan Injection Pediatrics</brief_title>
	<detailed_description>This company-sponsored study one-arm , prospective , , cohort-observational study pediatrics ( less 15 year old ) administer Ciproxan injection . All patient contract institute enrol study . Consequently 45 case plan enrolled three-year period Target population pediatrics diagnosis complicate cystitis , pyelonephritis , cystic fibrosis , anthrax infect ciprofloxacin-active microorganism , i.e . Bacillus anthracis , Escherichia coli , Pseudomonas aeruginosa . The treatment perform base product label Japan . The standard observation perform last date treatment .</detailed_description>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Cystitis</mesh_term>
	<mesh_term>Pyelonephritis</mesh_term>
	<mesh_term>Anthrax</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>Female male pediatric patient ( less 15 year old ) diagnosis complicate cystitis , pyelonephritis , cystic fibrosis , anthrax infect ciprofloxacinactive microorganism , i.e . Bacillus anthracis , Escherichia coli , Pseudomonas aeruginosa . Patients decision initiate treatment Ciproxan injection make per investigator 's routine treatment practice .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Ciprofloxacin</keyword>
	<keyword>Japan</keyword>
	<keyword>Post-marketing surveillance</keyword>
</DOC>